Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

HALF-YEAR REPORT 2015

Jean-Paul Clozel, CEO "We have had
an excellent first half of the year with
continued strong demand
for our products."
 

Jean-Paul Clozel, CEO "We have had
an excellent first half of the year with
continued strong demand
for our products."
 

Global Actelion

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 17:31:47 CET 31/07/2015
CHF 142,90Up Down image
+0,30 (+0,21%)